- Home
- YSXT vs ANL Comparison
YSXT vs ANL Comparison
Compare YSXT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSXT
- ANL
- Stock Information
- Founded
- YSXT 2011
- ANL 2004
- Country
- YSXT China
- ANL Cayman Islands
- Employees
- YSXT N/A
- ANL N/A
- Industry
- YSXT Automotive Aftermarket
- ANL
- Sector
- YSXT Consumer Discretionary
- ANL
- Exchange
- YSXT Nasdaq
- ANL Nasdaq
- Market Cap
- YSXT 58.6M
- ANL 61.8M
- IPO Year
- YSXT 2024
- ANL 2023
- Fundamental
- Price
- YSXT $2.49
- ANL $1.79
- Analyst Decision
- YSXT
- ANL Hold
- Analyst Count
- YSXT 0
- ANL 1
- Target Price
- YSXT N/A
- ANL N/A
- AVG Volume (30 Days)
- YSXT 713.3K
- ANL 11.3K
- Earning Date
- YSXT 07-31-2025
- ANL 10-21-2025
- Dividend Yield
- YSXT N/A
- ANL N/A
- EPS Growth
- YSXT N/A
- ANL N/A
- EPS
- YSXT 0.18
- ANL N/A
- Revenue
- YSXT $71,452,736.00
- ANL N/A
- Revenue This Year
- YSXT N/A
- ANL N/A
- Revenue Next Year
- YSXT N/A
- ANL N/A
- P/E Ratio
- YSXT $13.37
- ANL N/A
- Revenue Growth
- YSXT 22.04
- ANL N/A
- 52 Week Low
- YSXT $1.68
- ANL $1.10
- 52 Week High
- YSXT $9.96
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- YSXT 43.82
- ANL 55.55
- Support Level
- YSXT $2.52
- ANL $1.70
- Resistance Level
- YSXT $2.60
- ANL $1.82
- Average True Range (ATR)
- YSXT 0.29
- ANL 0.09
- MACD
- YSXT -0.02
- ANL -0.00
- Stochastic Oscillator
- YSXT 15.98
- ANL 60.33
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.